Holen Sie sich die Stockscreener-App
22.77
1.81%
0.51
Schlusskurs vom Vortag:
$22.26
Offen:
$22.16
24-Stunden-Volumen:
247.58K
Relative Volume:
0.39
Marktkapitalisierung:
$1.02B
Einnahmen:
$681.75M
Nettoeinkommen (Verlust:
$70.47M
KGV:
15.70
EPS:
1.45
Netto-Cashflow:
$173.19M
1W Leistung:
-4.05%
1M Leistung:
-16.44%
6M Leistung:
-9.24%
1J Leistung:
+38.86%
1-Tages-Spanne:
$22.02
$22.75
1-Wochen-Bereich:
$22.02
$23.83
52-Wochen-Spanne:
$16.00
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Firmenname
Pacira Biosciences Inc
Sektor
Telefon
650-242-8052
Adresse
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Vergleichen Sie PCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
22.75 | 1.00B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
143.04 | 63.05B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.77 | 43.33B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.15 | 40.43B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.07 | 22.97B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
433.01 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Hochstufung | Truist | Hold → Buy |
| 2025-01-30 | Hochstufung | Truist | Sell → Hold |
| 2024-08-13 | Herabstufung | Truist | Buy → Sell |
| 2024-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Fortgesetzt | JP Morgan | Overweight |
| 2023-12-20 | Eingeleitet | Raymond James | Outperform |
| 2023-08-03 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Fortgesetzt | Wedbush | Outperform |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-01-03 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-26 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Fortgesetzt | JP Morgan | Neutral |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-04-07 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-20 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-23 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Eingeleitet | BTIG Research | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-06 | Hochstufung | Mizuho | Underperform → Neutral |
| 2019-05-02 | Hochstufung | Stifel | Sell → Hold |
| 2019-02-01 | Herabstufung | Mizuho | Neutral → Underperform |
| 2018-08-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-21 | Bestätigt | Mizuho | Neutral |
| 2018-02-16 | Herabstufung | Needham | Buy → Hold |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-01-04 | Bestätigt | Canaccord Genuity | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Mkt Perform |
Alle ansehen
Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
Using Ichimoku Cloud for Pacira BioSciences Inc. technicalsWeekly Profit Summary & Risk Managed Investment Entry Signals - newser.com
Chart based analysis of Pacira BioSciences Inc. trendsJuly 2025 Catalysts & Weekly Setup with ROI Potential - newser.com
Will Pacira BioSciences Inc. (82P) stock split increase liquidity2025 Top Gainers & Verified Short-Term Trading Plans - newser.com
Can a trend reversal in Pacira BioSciences Inc. lead to recoveryEarnings Recap Summary & Low Volatility Stock Recommendations - newser.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out - ACCESS Newswire
How Pacira BioSciences Inc. (82P) stock behaves under inflation pressureWeekly Earnings Recap & Low Risk High Reward Ideas - newser.com
Pacira BioSciences (NASDAQ:PCRX) Given "Sell (D)" Rating at Weiss Ratings - MarketBeat
How to interpret RSI for Pacira BioSciences Inc. stock2025 Big Picture & Advanced Swing Trade Entry Plans - newser.com
Detecting support and resistance levels for Pacira BioSciences Inc.July 2025 Sector Moves & Fast Entry and Exit Trade Plans - newser.com
Pacira BioSciences Inc. stock trend outlook and recovery path2025 Major Catalysts & Weekly Chart Analysis and Trade Guides - newser.com
What moving averages say about Pacira BioSciences Inc.Weekly Trend Report & Weekly Top Gainers Alerts - newser.com
Pacira BioSciences Inc. stock volume spike explained2025 Price Targets & Fast Entry High Yield Stock Tips - newser.com
What momentum shifts mean for Pacira BioSciences Inc.Inflation Watch & Consistent Return Investment Signals - newser.com
Custom watchlist performance reports with Pacira BioSciences Inc.2025 Stock Rankings & Growth Oriented Trading Recommendations - newser.com
Pacira BioSciences Becomes Oversold (PCRX) - Nasdaq
Pacira BioSciences, Inc. $PCRX Shares Bought by Gagnon Securities LLC - MarketBeat
Gagnon Advisors LLC Has $5.10 Million Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Robeco Institutional Asset Management B.V. Has $1.29 Million Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira Biosciences, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Possible Bearish Signals With Pacira BioSciences Insiders Disposing Stock - simplywall.st
Raymond James Maintains Pacira BioSciences(PCRX.US) With Hold Rating - 富途牛牛
Applying Elliott Wave Theory to Pacira BioSciences Inc.Fed Meeting & Smart Money Movement Alerts - newser.com
Long term hold vs stop loss in Pacira BioSciences Inc.July 2025 Macro Moves & Stepwise Trade Signal Implementation - newser.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect - ACCESS Newswire
Will Pacira BioSciences Inc. stock gain from government policiesWeekly Risk Report & Capital Efficiency Focused Strategies - newser.com
Using Bollinger Bands to evaluate Pacira BioSciences Inc.Chart Signals & Entry Point Confirmation Alerts - newser.com
Can Pacira BioSciences Inc. (82P) stock hold up in economic slowdownPrice Action & Daily Stock Momentum Reports - newser.com
Greenwood Capital Associates LLC Takes $314,000 Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Why Institutions Believe Medinova Diagnostic Services Limited Is Undervalued TodayDividend Aristocrats List & Free Unlock Portfolio Growth - earlytimes.in
What drives Pacira BioSciences Inc stock priceLarge Cap Stability Picks & Today’s Picks, Tomorrow’s Winners - earlytimes.in
Pacira Biosciences (PCRX) Grants Inducement Awards to New Employ - GuruFocus
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Pacira BioSciences reports inducement grants - MarketScreener
50,600 Shares: Pacira Grants Inducement Awards to 15 New Employees; $24.58 Exercise Price - Stock Titan
Why Pacira BioSciences Inc. (82P) stock could outperform next yearPortfolio Performance Summary & Growth Focused Investment Plans - newser.com
Farther Finance Advisors LLC Boosts Holdings in Pacira BioSciences, Inc. $PCRX - Defense World
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Is Ganga Forging Limited Still a Good Stock to Buy After Recent EarningsSupport Zone Identification & Big Profit Small Budget - earlytimes.in
Finanzdaten der Pacira Biosciences Inc-Aktie (PCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.00%
2.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):